Cargando…

Immune‐related lncRNA signature delineates an immune‐excluded subtype of liver cancer with unfavorable clinical outcomes

BACKGROUND: Long non‐coding RNAs (lncRNAs) play crucial roles in immune regulation and, therefore, may be closely related to the tumor microenvironment (TME). However, there are few studies regarding the relationship between the lncRNAs and the TME in liver cancer. METHODS: Firstly, we constructed a...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yawei, Xi, Leying, Wei, Lihui, Sun, Debin, Zeng, Tianmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906039/
https://www.ncbi.nlm.nih.gov/pubmed/35040184
http://dx.doi.org/10.1002/jcla.24244
_version_ 1784665318637961216
author Chen, Yawei
Xi, Leying
Wei, Lihui
Sun, Debin
Zeng, Tianmei
author_facet Chen, Yawei
Xi, Leying
Wei, Lihui
Sun, Debin
Zeng, Tianmei
author_sort Chen, Yawei
collection PubMed
description BACKGROUND: Long non‐coding RNAs (lncRNAs) play crucial roles in immune regulation and, therefore, may be closely related to the tumor microenvironment (TME). However, there are few studies regarding the relationship between the lncRNAs and the TME in liver cancer. METHODS: Firstly, we constructed a lncRNA signature based on the top 10 immune‐inversely related lncRNAs obtained from the ImmLnc database and performed disease‐free survival (DFS) and overall survival (OS) analyses for the patients included in the Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA‐LIHC) stratified by the lncRNA signature. Then, we explored the relationship between the lncRNA signature with distinct mutation profiles and the tumor microenvironment (TME). RESULTS: The lncRNA signature was successfully constructed and verified by survival analysis. The high lncRNA signature was correlated with a decreased DFS and OS in liver cancer and other two gastrointestinal cancers. The mutation profiles showed that the Lnc_high group had a higher number of mutations on many genes, mostly enriched in p53 and WNT pathways. The TME results showed that the Lnc_high group had the highest proportion (51%) of lymphocyte depletion‐characterized immune subtype, and a higher expression of immune checkpoint molecules such as LAG3, PD‐L1, CTLA4. On the contrary, in the Lnc_low group, infiltrating immune‐cell proportions were significantly higher, and a significant enhancement of four axes of the cancer immunity cycle immunogram was observed in this group. CONCLUSIONS: The lncRNA signature we constructed identified an immune‐excluded subtype of liver cancer with unfavorable clinic outcomes, which could be tested as a biomarker for immunotherapy in the future.
format Online
Article
Text
id pubmed-8906039
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-89060392022-03-10 Immune‐related lncRNA signature delineates an immune‐excluded subtype of liver cancer with unfavorable clinical outcomes Chen, Yawei Xi, Leying Wei, Lihui Sun, Debin Zeng, Tianmei J Clin Lab Anal Research Articles BACKGROUND: Long non‐coding RNAs (lncRNAs) play crucial roles in immune regulation and, therefore, may be closely related to the tumor microenvironment (TME). However, there are few studies regarding the relationship between the lncRNAs and the TME in liver cancer. METHODS: Firstly, we constructed a lncRNA signature based on the top 10 immune‐inversely related lncRNAs obtained from the ImmLnc database and performed disease‐free survival (DFS) and overall survival (OS) analyses for the patients included in the Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA‐LIHC) stratified by the lncRNA signature. Then, we explored the relationship between the lncRNA signature with distinct mutation profiles and the tumor microenvironment (TME). RESULTS: The lncRNA signature was successfully constructed and verified by survival analysis. The high lncRNA signature was correlated with a decreased DFS and OS in liver cancer and other two gastrointestinal cancers. The mutation profiles showed that the Lnc_high group had a higher number of mutations on many genes, mostly enriched in p53 and WNT pathways. The TME results showed that the Lnc_high group had the highest proportion (51%) of lymphocyte depletion‐characterized immune subtype, and a higher expression of immune checkpoint molecules such as LAG3, PD‐L1, CTLA4. On the contrary, in the Lnc_low group, infiltrating immune‐cell proportions were significantly higher, and a significant enhancement of four axes of the cancer immunity cycle immunogram was observed in this group. CONCLUSIONS: The lncRNA signature we constructed identified an immune‐excluded subtype of liver cancer with unfavorable clinic outcomes, which could be tested as a biomarker for immunotherapy in the future. John Wiley and Sons Inc. 2022-01-18 /pmc/articles/PMC8906039/ /pubmed/35040184 http://dx.doi.org/10.1002/jcla.24244 Text en © 2022 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Chen, Yawei
Xi, Leying
Wei, Lihui
Sun, Debin
Zeng, Tianmei
Immune‐related lncRNA signature delineates an immune‐excluded subtype of liver cancer with unfavorable clinical outcomes
title Immune‐related lncRNA signature delineates an immune‐excluded subtype of liver cancer with unfavorable clinical outcomes
title_full Immune‐related lncRNA signature delineates an immune‐excluded subtype of liver cancer with unfavorable clinical outcomes
title_fullStr Immune‐related lncRNA signature delineates an immune‐excluded subtype of liver cancer with unfavorable clinical outcomes
title_full_unstemmed Immune‐related lncRNA signature delineates an immune‐excluded subtype of liver cancer with unfavorable clinical outcomes
title_short Immune‐related lncRNA signature delineates an immune‐excluded subtype of liver cancer with unfavorable clinical outcomes
title_sort immune‐related lncrna signature delineates an immune‐excluded subtype of liver cancer with unfavorable clinical outcomes
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8906039/
https://www.ncbi.nlm.nih.gov/pubmed/35040184
http://dx.doi.org/10.1002/jcla.24244
work_keys_str_mv AT chenyawei immunerelatedlncrnasignaturedelineatesanimmuneexcludedsubtypeoflivercancerwithunfavorableclinicaloutcomes
AT xileying immunerelatedlncrnasignaturedelineatesanimmuneexcludedsubtypeoflivercancerwithunfavorableclinicaloutcomes
AT weilihui immunerelatedlncrnasignaturedelineatesanimmuneexcludedsubtypeoflivercancerwithunfavorableclinicaloutcomes
AT sundebin immunerelatedlncrnasignaturedelineatesanimmuneexcludedsubtypeoflivercancerwithunfavorableclinicaloutcomes
AT zengtianmei immunerelatedlncrnasignaturedelineatesanimmuneexcludedsubtypeoflivercancerwithunfavorableclinicaloutcomes